Announcements Trials
Browse Landscape

Phase

Phase 2/3 2

Status

Completed 2

Sponsor Class

OTHER 13INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Polyps 2Hyperplasia 2Adenomatous Polyps 1Adenomatous Polyposis Coli 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Eicosapentaenoic Acid × Clear all
NCT00510692 2014-08-22

Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA

S.L.A. Pharma AG

Phase 2/3 Completed
58 enrolled 12 charts
Gastrointestinal

Hyperplasia, Adenomatous Polyposis Coli, Polyps

NCT00432913 2008-10-17

Effect of 2 Doses of EPA on Apoptosis and Cell Proliferation on Colon Mucosa

S.L.A. Pharma AG

Phase 2/3 Completed
120 enrolled

Hyperplasia, Polyps, Adenomatous Polyps

Data powered by HemOnc (CC BY 4.0) Colophon âš¡